- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03533023
The Healthy Heroes Study
Optimizing Circadian Rhythms by Regulating Eating Patterns to Reduce Cardiometabolic Disease Risk Among Firefighters--The Healthy Heroes Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
As per recommendations from the fire department, fire department unions, and funding agencies, we did not require compromised health measures (e.g. hyperglycemia, hypertension, etc.) as inclusion criteria for they would be discriminatory against some firefighters.
Inclusion Criteria:
- Firefighter or work a 24-hr shift schedule with San Diego Fire and Rescue
- Age: 21-65 years
- Own a smartphone (Apple or Android Operating System)
- If participants are on cardiovascular medications (HMG-CoA reductase inhibitors (statins), other lipid modifying drugs (including over the counter drugs such as red yeast rice and fish oil), anti-hypertensive, anti-diabetes drugs), no dose adjustments will be allowed during the study period
Exclusion Criteria:
- Insulin-dependent diabetes mellitus
- Presence of acute chronic inflammatory or autoimmune disease (defined by acute symptoms or C-reactive protein >10 mg/L), malabsorption syndromes, liver disease, or kidney disease (stage 3 or greater)
- Uncontrolled thyroid disease
- Intake of drugs likely to interfere with study endpoints, including corticosteroids, anabolic steroids, anti-psychotics, antiretroviral drugs, and immunosuppressive drugs (within 3 months of starting the study)
- Presence or recent history of anemia (hematocrit <33% within 3 months of starting the study)
- History of bariatric surgery
- Pregnant or breast-feeding women
- Current or recent (within 12 months of starting the study) pregnancy or breastfeeding, or intention of becoming pregnant in the next 6 months
- Any cancer other than non-melanoma skin cancer in the last 3 years
- On a special or prescribed diet for other reasons (e.g. Celiac disease)
- Depression determined by the Beck Depression Inventory (BDI)
- Planned international travel during study period
- Insufficient logging on the mCC app (does not log at least 2 entries a day for 10 of 14 days) during baseline will exclude from being randomized into the intervention period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TRE + SOC
Time Restricted Eating + Standard of Care
|
Participants in this arm will adhere to a daily, consistent 10-hr eating window for the course of the study as well as receive nutritional counseling from the study dietician.
Other Names:
|
OTHER: SOC
Standard of Care
|
Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt a 10-hr eating window.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the impact of TRE on glucose homeostasis at end of intervention compared to baseline
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured by an ambulatory continuous glucose monitoring device and blood work throughout the study. Note: Significant changes expected in participants who had elevated glucose homeostasis at baseline. No significant changes expected in those within normal ranges at baseline. Primary endpoint analysis will be done by comparing baseline and 12-week intervention. |
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Assess the feasibility and adherence of TRE
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured by percentage of days logged that participants ate within their 10-hour window and by end of study responses. Note: Significant changes expected in participants in the TRE arm of the study on and off shift. No significant changes expected in the standard of care arm of the study. Primary endpoint analysis will be done by comparing baseline and 12-week intervention. |
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess changes in metabolic biomarkers in response to TRE at end of intervention compared to baseline
Time Frame: Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured with blood biochemistry.Measured with blood biochemistry under TRE, including, but not limited to: fasting glucose, HbA1c, cholesterol, and triglycerides. Note: Significant changes expected in participants who had abnormal levels at baseline (e.g. elevated LDL cholesterol, low HDL cholesterol, elevated triglycerides). No significant changes expected in those were within normal ranges at baseline. |
Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Systolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline
Time Frame: Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured at baseline and during TRE intervention.
Note: Significant changes expected in participants who had elevated systolic blood pressure at baseline.
No significant changes expected in those without elevated systolic blood pressure at baseline.
|
Timeframe: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Diastolic blood pressure (mmHg) in response to TRE at end of intervention compared to baseline
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured at baseline and during TRE intervention.
Note: Significant changes expected in participants who had elevated diastolic blood pressure at baseline.
No significant changes expected in those without elevated diastolic blood pressure at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Body weight (kg)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured on a digital scale.
Note: Significant changes expected in participants who had elevated weight at baseline.
No significant changes expected in those who were not overweight at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body mass index (kg/m^2)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Calculated from body weight (kg) and height (m).
Note: Significant changes expected in participants who had elevated BMI at baseline.
No significant changes expected in those whose BMI was not elevated at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Waist and hip circumference (cm)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured with standardized body tape measure.
Note: Significant changes expected in participants who had increased waist and hip circumference at baseline.
No significant changes expected in those without increased waist and hip circumference at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Hip (cm)/waist (cm) ratio
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured using tape measure.
Note: Significant changes expected in participants who had an increased hip/waist ratio at baseline.
No significant changes expected in those without increases at baseline
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Body composition including but not limited to fat percentage (%), fat mass (kg), and lean mass (kg)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured by Tanita Digital Scale.
Note: Significant changes expected in participants who had elevations levels at baseline.
No significant changes expected in those without elevations at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Questionnaires (quality of life, sleep, and health)
Time Frame: primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Measured by SF-36, PSQI, and ESS.
Note: Significant changes expected in participants who had decreased self-reporting of the above-mentioned questionnaires at baseline.
No significant changes expected in those without decreases at baseline.
|
primary endpoint=12-week intervention (compared to 2-week baseline); follow-up will be at 1-year
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Manoogian ENC, Zadourian A, Lo HC, Gutierrez NR, Shoghi A, Rosander A, Pazargadi A, Ormiston CK, Wang X, Sui J, Hou Z, Fleischer JG, Golshan S, Taub PR, Panda S. Feasibility of time-restricted eating and impacts on cardiometabolic health in 24-h shift workers: The Healthy Heroes randomized control trial. Cell Metab. 2022 Oct 4;34(10):1442-1456.e7. doi: 10.1016/j.cmet.2022.08.018.
- Manoogian ENC, Zadourian A, Lo HC, Gutierrez NR, Shoghi A, Rosander A, Pazargadi A, Wang X, Fleischer JG, Golshan S, Taub PR, Panda S. Protocol for a randomised controlled trial on the feasibility and effects of 10-hour time-restricted eating on cardiometabolic disease risk among career firefighters doing 24-hour shift work: the Healthy Heroes Study. BMJ Open. 2021 Jun 16;11(6):e045537. doi: 10.1136/bmjopen-2020-045537.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 172083
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fasting
-
USDA, Western Human Nutrition Research CenterUniversity of California, DavisCompletedCardiovascular Risk Factor | Athletic Performance | Fasting | Resting Energy Expenditure | Intermittent FastingUnited States
-
Desitin Arzneimittel GmbHBioPharma Services, IncCompleted
-
Beth Israel Deaconess Medical CenterCompleted
-
Gaziosmanpasa Research and Education HospitalCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Chulalongkorn UniversityCompleted
-
IPCA Laboratories Ltd.Completed
-
IPCA Laboratories Ltd.Completed
-
Dr. Reddy's Laboratories LimitedCompleted
Clinical Trials on Time Restricted Eating + Standard of Care
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Salk...Active, not recruitingMetabolic Syndrome | Pre-DiabetesUnited States
-
University of California, San DiegoSalk Institute for Biological StudiesActive, not recruiting
-
University of California, San DiegoSalk Institute for Biological StudiesRecruitingDiabetes Mellitus, Type 2 | Diabetes type2 | Time Restricted FeedingUnited States
-
Norwegian University of Science and TechnologySt. Olavs HospitalActive, not recruitingGestational DiabetesNorway
-
Universidad de GranadaUniversidad Pública de NavarraCompletedObesity, Abdominal | Time Restricted Feeding | Cardiometabolic SyndromeSpain
-
Children's Hospital Los AngelesRecruitingPediatric Obesity | Time Restricted Feeding | Time Restricted EatingUnited States
-
University of TorontoUniversity Health Network, TorontoRecruiting
-
University of Illinois at ChicagoRecruiting
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingMetabolic Syndrome | Overweight and Obesity | Time Restricted Eating
-
Universidad de GranadaRecruitingObesity | Exercise | Hepatic Steatosis | Time Restricted Feeding | Cardiometabolic SyndromeSpain